title: The special role of ultrasound for screening, staging and surveillance of malignant ovarian tumors: distinction from other methods of diagnostic imaging.
abstract: Ovarian cancer is the most aggressive gynecologic malignancy, with a 5-year survival rate ranging around 40%. A crucial factor influencing the prognosis is early detection of a suspicious mass and referral to a gynecologic oncology center for further diagnosis, staging and debulking surgery. Here, we present the different imaging methods ultrasound (US), magnetic resonance imaging, computer tomography (CT) and 18F-fluoro-deoxyglucose positron emission tomography (PET)/CT that are used for the characterization, diagnosis, staging and surveillance of ovarian cancer. In this review, we focus on US and discuss in detail the advantages and the limitations, as well as the appropriate indications for each of the individual imaging techniques.
authors.affiliation: Ultrasound Unit, Department of Gynecology and Obstetrics, University Hospital of Basel, Basel, Switzerland, gwendolin.manegold-brauer@usb.ch.
authors.forename: Gwendolin
authors.initials: G
authors.lastname: Manegold-Brauer
authors.forename: Anjeung Kang
authors.initials: AK
authors.lastname: Bellin
authors.forename: Sevgi
authors.initials: S
authors.lastname: Tercanli
authors.forename: Olav
authors.initials: O
authors.lastname: Lapaire
authors.forename: Viola
authors.initials: V
authors.lastname: Heinzelmann-Schwarz
mesh_terms: D003287:Contrast Media; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D008403:Mass Screening; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000000981:diagnostic imaging* / Q000473:pathology; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D014057:Tomography, X-Ray Computed; D014463:Ultrasonography
chemical_list: D003287:Contrast Media; D019275:Radiopharmaceuticals